AR065669A1 - COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTI-HERITAGE AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS - Google Patents
COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTI-HERITAGE AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONSInfo
- Publication number
- AR065669A1 AR065669A1 ARP080100976A ARP080100976A AR065669A1 AR 065669 A1 AR065669 A1 AR 065669A1 AR P080100976 A ARP080100976 A AR P080100976A AR P080100976 A ARP080100976 A AR P080100976A AR 065669 A1 AR065669 A1 AR 065669A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical
- diabetic
- lipoate
- pharmaceutical composition
- metformin
- Prior art date
Links
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 title abstract 3
- 230000000598 lipoate effect Effects 0.000 title abstract 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003105 metformin Drugs 0.000 title abstract 3
- 208000002249 Diabetes Complications Diseases 0.000 title abstract 2
- 206010012655 Diabetic complications Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000000651 prodrug Substances 0.000 abstract 3
- 229940002612 prodrug Drugs 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- 239000005541 ACE inhibitor Substances 0.000 abstract 2
- 108010061435 Enalapril Proteins 0.000 abstract 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 abstract 1
- SYPAAUOZTIBVHX-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O SYPAAUOZTIBVHX-UHFFFAOYSA-N 0.000 abstract 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 abstract 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 abstract 1
- 102000015427 Angiotensins Human genes 0.000 abstract 1
- 108010064733 Angiotensins Proteins 0.000 abstract 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical group C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 abstract 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 abstract 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 abstract 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 abstract 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 abstract 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 229960004530 benazepril Drugs 0.000 abstract 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 abstract 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 abstract 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 abstract 1
- 229960000873 enalapril Drugs 0.000 abstract 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 abstract 1
- 229960000309 enalapril maleate Drugs 0.000 abstract 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical group OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 abstract 1
- -1 format Chemical compound 0.000 abstract 1
- 229940050410 gluconate Drugs 0.000 abstract 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 abstract 1
- 229940099584 lactobionate Drugs 0.000 abstract 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 abstract 1
- 229940095102 methyl benzoate Drugs 0.000 abstract 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 abstract 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 abstract 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 abstract 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 abstract 1
- 229940049953 phenylacetate Drugs 0.000 abstract 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 abstract 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 abstract 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 abstract 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 abstract 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 abstract 1
- 229940116351 sebacate Drugs 0.000 abstract 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 abstract 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 abstract 1
- 229940071104 xylenesulfonate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones farmacéuticas, métodos y kits, formas farmacéuticas que comprenden metformina R-(+) lipoato y un agente antihipertensivo o una sal aceptable en términos farmacéuticos, hidrato, solvato y profármaco derivada de estos para el tratamientode la hiperglucemia diabética Tipo 2 y las complicaciones diabéticas. Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende metformina R-(+) lipoato, y un inhibidor de enzima de conversion de angiotensina (ACE) o una salaceptable en términos farmacéuticos, hidrato, solvato o un profármaco derivado de estos. Reivindicacion 2: La composicion farmacéutica de la reivindicacion 1, caracterizada porque el inhibidor ACE se selecciona del grupo conformado por benazepril,enalapril y ramipil, o una sal aceptable en términos farmacéuticos, sal, hidrato, solvato y un profármaco derivado de estos. Reivindicacion 5: Una composicion farmacéutica de la reivindicacion 4 caracterizada porque la sal aceptable en términosfarmacéuticos se selecciona del grupo conformado por un propionato, decanoato, caprilato, acrilato, formato, isobutirato, caprato, heptanoato, propiolato, oxalato, malonato, succinato, suberato, sebacato, fumarato, maleato, butina-1,4-dioato, hexina-1,6-dioato, benzoato, clorobenzoato, metilbenzoato, dinitrobenzoato, hidroxibenzoato, metoxibenzoato, ftalato, tereftalato, sulfonato, xilenosulfonato, fenilacetato, fenilpropionato, fenilbutirato, citrato, lactato, beta-hidroxibutirato, glicolato,tartrato, metanosulfonato, propanosulfonatos, naftaleno-1-sulfonato, naftaleno-2-sulfonato, mandelato, hipurato, gluconato, o lactobionato. Reivindicacion 8: Una composicion farmacéutica de la reivindicacion 4 caracterizada porque el inhibidorACE es enalapril maleato.Pharmaceutical compositions, methods and kits, pharmaceutical forms comprising metformin R - (+) lipoate and an antihypertensive agent or an acceptable salt in pharmaceutical terms, hydrate, solvate and prodrug derived therefrom for the treatment of Type 2 diabetic hyperglycemia and diabetic complications . Claim 1: A pharmaceutical composition characterized in that it comprises metformin R - (+) lipoate, and an angiotensin conversion enzyme (ACE) inhibitor or a salaceptable in pharmaceutical terms, hydrate, solvate or a prodrug derived therefrom. Claim 2: The pharmaceutical composition of claim 1, characterized in that the ACE inhibitor is selected from the group consisting of benazepril, enalapril and ramipil, or a salt acceptable in pharmaceutical terms, salt, hydrate, solvate and a prodrug derived therefrom. Claim 5: A pharmaceutical composition of claim 4 characterized in that the salt acceptable in pharmaceutical terms is selected from the group consisting of a propionate, decanoate, caprylate, acrylate, format, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butine-1,4-dioate, hexin-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, citrate Lactate, beta-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonates, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, hippurate, gluconate, or lactobionate. Claim 8: A pharmaceutical composition of claim 4 characterized in that the ACE inhibitor is enalapril maleate.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90593507P | 2007-03-09 | 2007-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065669A1 true AR065669A1 (en) | 2009-06-24 |
Family
ID=39759819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100976A AR065669A1 (en) | 2007-03-09 | 2008-03-07 | COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTI-HERITAGE AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR065669A1 (en) |
| CL (1) | CL2008000683A1 (en) |
| TW (1) | TW200848012A (en) |
| WO (1) | WO2008112167A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101190953B1 (en) * | 2009-08-25 | 2012-10-12 | 한올바이오파마주식회사 | Metformin taurine salt, preparation method thereof, pharmaceutical composition comprising the same and combination preparation comprising the same |
| WO2011025270A2 (en) * | 2009-08-25 | 2011-03-03 | 한올바이오파마주식회사 | Metformin caffeic acid salt, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same |
| WO2011025267A2 (en) * | 2009-08-25 | 2011-03-03 | 한올바이오파마주식회사 | Metformin methanesulfonate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same |
| EP2599481A1 (en) * | 2011-11-30 | 2013-06-05 | Lunamed AG | 4-phenylbutyric acid for the treatment or prevention of various diseases |
| EP2727587A1 (en) * | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| WO2015063140A1 (en) * | 2013-10-30 | 2015-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| US20180110762A1 (en) * | 2015-03-26 | 2018-04-26 | Merck Sharp & Dohme Corp | Compositions Methods for Treating Chronic Kidney Disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693094B2 (en) * | 2001-03-22 | 2004-02-17 | Chrono Rx Llc | Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
| US20030220301A1 (en) * | 2002-02-14 | 2003-11-27 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
| BRPI0409136A (en) * | 2003-04-09 | 2006-04-25 | Japan Tobacco Inc | pentacyclic heteroaromatic compound and medicinal use thereof |
| US20060154971A1 (en) * | 2005-01-13 | 2006-07-13 | Navitas Pharma | Combination therapies of cicletanine and lacidipine |
-
2008
- 2008-03-07 CL CL200800683A patent/CL2008000683A1/en unknown
- 2008-03-07 AR ARP080100976A patent/AR065669A1/en unknown
- 2008-03-07 WO PCT/US2008/003095 patent/WO2008112167A1/en not_active Ceased
- 2008-03-07 TW TW097108034A patent/TW200848012A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008000683A1 (en) | 2008-08-01 |
| WO2008112167A1 (en) | 2008-09-18 |
| TW200848012A (en) | 2008-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065669A1 (en) | COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTI-HERITAGE AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS | |
| NI200800060A (en) | BENCIMIDAZOLS REPLACED AS CINASA INHIBITORS. | |
| AR030893A1 (en) | COMBINED USE OF GABAA ACETILCOLINESTERASE INHIBITORS AND INVESTED AGONISTS FOR THE TREATMENT OF COGNITIVE DISORDERS | |
| GT200500102A (en) | ORTOSUSTITUTED ARIL-O-HETEROARILAMIDE COMPOUNDS | |
| PE20081831A1 (en) | DERIVATIVES OF HETEROARIL-PYRROLIDINIL- AND -PIPERIDINIL-KETONE | |
| ECSP045407A (en) | BENZAZOLES SUBSTITUTED AND THE USE OF THE SAME AS INHIBITORS OF QUINASA RAF | |
| EA200971104A1 (en) | Derivatives of benzimidazole | |
| ECSP077980A (en) | AKT ACTIVITY INHIBITORS | |
| ECSP056131A (en) | CARBON COMPOUNDS | |
| HN2005000212A (en) | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
| PE20110300A1 (en) | PIRROL COMPOUNDS AS INHIBITORS OF THE PROTON PUMP | |
| PE20090109A1 (en) | PYRROLIC COMPOUNDS AS INHIDORS OF THE PROTON PUMP | |
| CR10095A (en) | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
| HN2005000476A (en) | ENANTIOMERALLY PURE AMINOHETEROARILO COMPOUNDS AS PROTEIN QUINASE INHIBITORS | |
| GT200800158A (en) | PIRAZOLQUINOLONAS AS POWERFUL PARP INHIBITORS | |
| ECSP066362A (en) | INHIBITORS OF MYTHOTIC KINESINE. | |
| DK1663242T3 (en) | 2,4-Pyrimidinediamine compounds and use as antiproliferative agents | |
| CO6290654A2 (en) | SALINOSPORAMIDA DERIVATIVES AS PROTEASOMA INHIBITORS | |
| EA201270546A1 (en) | SUBSTITUTED PIPERIDINES, WHICH INCREASE P53 ACTIVITY AND THEIR APPLICATION | |
| PE20110931A1 (en) | PYRROLIDIN-2-ONAS AS HDM2 LIGANDS | |
| CR20130659A (en) | COMPOUNDS FOR ADDICTION TREATMENT | |
| WO2006024492A3 (en) | Medical implant provided with inhibitors of atp synthesis | |
| MX2009000657A (en) | Compositions and methods for the treatment of mucositis. | |
| BRPI0813748A2 (en) | crystalline form i, compound, process for the preparation of crystalline form i, weed protection agent, and process for combating unwanted plant growth | |
| EA201100755A1 (en) | METHOD OF TREATMENT OR PREVENTION OF THROMBOSIS BY USING DABIGATRANE ETHSYLATE OR ITS SALT WITH IMPROVED EFFICIENCY IN COMPARISON WITH STANDARD TREATMENT WARFARIN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |